MRK: Merck Stock a Strong Performer In the Pharma Space
Revenues also came in higher than expected, with the company reporting $10.39 billion in revenue versus the analysts’ consensus of $10.2 billion. It was a solid beat on both the top and bottom lines with the company seeing strength across their various business segments. Honeywell did say that they remain cautious on the global economy but believe that the company is well positioned for outperformance over the next five years. The backorders at the company grew to $15.5 billion and margins also improved in the quarter. The only negative we took away from our first read of the release is that Honeywell’s guidance on the revenue front is a bit below the analyst consensus for 2014.
Investors Should Focus On What They Can Control
Id like to take a look at whats happening with this giant company and what it could mean for investors. Lets jump right in. Company Profile Although the Merck name stretches back to 1891, the company as we know it was created in 2009 when Merck and Schering-Plough merged to create the second-largest healthcare company in the world. The company boasts a diverse portfolio of medical treatments and products, including vaccines, prescription drugs and pet meds. And the company is also behind a number of wildly popular consumer products, including Dr Scholls gel inserts and orthotics, Lotrimin Athletes Foot treatment and A+D ointment.
Japanese Stocks: BUY 17.9 million shares SELL the hotist stock now 12.1 million shares —————————————————— BUY 5.8 million shares FILED UNDER: Reprints We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/ Comments (0) Be the first to comment on reuters.com.
TABLE-Foreign brokers set to buy Japanese stocks
Whatever the case, the bigger concern is how long the selloff will last. Of course, nobody knows for sure how long any selloff will last. To keep things in context, keep in mind that stocks rallied about 30% last year. Thats a rather large one-year return.